title: Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins.
abstract: Recombinant bacille Calmette-Guerin (BCG) based vaccine delivery systems could potentially share the safety and effectiveness of BCG. We therefore prepared recombinant BCG vaccines which expressed the L1 late protein of the human papillomavirus (HPV) 6b or the E7 early protein of the HPV 16. The two recombinants were evaluated as immunogens in C57BL/6J and BALB/c mice, and compared with a conventional protein/adjuvant system using E7 or L1 mixed with Quil-A adjuvant. rBCG6bL1 and rBCG16E7 primed specific immune responses, represented by DTH, T-proliferation and antibody, and rBCG16E7 induced cytotoxic immune response to E7 protein. The magnitude of the observed responses were less than those elicited by protein/adjuvant vaccine. As recombinant BCG vaccines expressing HPV6bL1 or HPV16E7 persist at low levels in the immunised host, they may be beneficial to prime or retain memory responses to antigens, but are unlikely to be useful as a single component vaccine strategy.
authors.affiliation: Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia.
authors.forename: I A
authors.initials: IA
authors.lastname: Jabbar
authors.forename: G J
authors.initials: GJ
authors.lastname: Fernando
authors.forename: N
authors.initials: N
authors.lastname: Saunders
authors.forename: A
authors.initials: A
authors.lastname: Aldovini
authors.forename: R
authors.initials: R
authors.lastname: Young
authors.forename: K
authors.initials: K
authors.lastname: Malcolm
authors.forename: I H
authors.initials: IH
authors.lastname: Frazer
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D001500:BCG Vaccine / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D001483:Base Sequence; D036022:Capsid Proteins; D003001:Cloning, Molecular; D017931:DNA Primers / Q000235:genetics; D006801:Humans; D006968:Hypersensitivity, Delayed; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology*; D027383:Papillomaviridae / Q000235:genetics / Q000276:immunology*; D050725:Papillomavirus E7 Proteins; D010957:Plasmids / Q000235:genetics; D013601:T-Lymphocytes / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014764:Viral Proteins
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D001500:BCG Vaccine; D036022:Capsid Proteins; D017931:DNA Primers; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D014614:Vaccines, Synthetic; D014764:Viral Proteins; C059731:oncogene protein E7, Human papillomavirus type 16; C091560:L1 protein, Human papillomavirus type 6